The full-length cDNA for the human retinoic acid receptor-yl (RAR-yl) has been expressed to high levels in Spodoptera frugiferda (Sf9) 
INTRODUCTION
Retinoic acid (RA), which is derived from vitamin A, is a key regulator of cellular growth and differentiation. RA and its synthetic analogues (retinoids) are used therapeutically in the prevention and treatment of skin diseases and certain malignancies [1] [2] [3] [4] [5] . The molecular mechanisms through which retinoids act are largely unknown. Recently two related families of nuclear receptors for all-trans-RA (RARs) [6] [7] [8] [9] [10] [11] and its 9-cis stereoisomer (RXRs) [12] [13] [14] [15] [16] [17] have been identified. Three distinct RAR (RAR-a, -fl and -y) and RXR (RXR-a, -,8 and -y) genes have been cloned, and it has been demonstrated that heterodimerization of RARs and RXRs increases the efficiency of binding to certain cognate response elements (RAREs) [13, 15] . RARs are members of the superfamily of nuclear receptors (reviewed in [18] ) and act as ligand-dependent transcriptional enhancer factors. Differential promoter usage and alternative splicing generate multiple isoforms of each RAR member, which differ in their N-terminal sequences [19, 20] . The three major RAR gene products (RAR-al, -p2 and -yl) display differential tissue distributions, suggesting that they may possess functional specificity [21, 22] . Several genes containing a functional RARE have been identified, and are generally composed of direct repeats of the motif 5'-GTTCA or 5'-GGTCA, or closely related sequences [23] [24] [25] [26] [27] [28] .
Most studies to date on the regulation of RAR expression have described measurements of RAR mRNA levels by Northern blot analysis or in situ hybridization [29] [30] [31] . In these studies, it has been assumed that relative amounts and changes in mRNA levels reflect similar changes in functional receptor protein. The lack of information concerning the regulation and properties of RARs stems from their low abundance in cells, which express on average 1000 RAR molecules per cell [32] . This small number makes detection of functional RARs by standard ligand-binding assays or immunological methods difficult, and makes purification of RARs from these sources for the purposes of structural and functional characterization not technically feasible.
To obtain sufficient amounts of receptor for functional and structural studies, we have utilized the baculovirus and vaccinia virus expression systems to express large quantities of full-length human RAR-yl in Spodoptera frugiferda (Sf9) insect cells and HeLa cells, respectively. The recombinant RAR-yl was partially purified and its ligand-and DNA-binding properties examined. A comparative analysis revealed no differences between RAR-yl overexpressed in mammalian (HeLa) or insect (Sf9) cells. Oxidized RA metabolites, generally believed to have little biological activity [33, 34] , bound to RAR-yl, although with significantly lower apparent affinity than RA. The availability of large quantities of RARs, obtained through the baculovirus expression system, will allow in-depth functional and structural studies to be realized. 
Culture of Sf9 cells
Sf9 cells were grown at 27°C in monolayer culture, in TNM-FH medium [35, 36] supplemented with 10 % fetal bovine serum, 100 ,g of streptomycin/ml, 100 units of penicillin/ml and 125 ng of amphotericin B/ml. For expression of RAR-yl, cells were adapted to, and grown in, serum-free growth medium (ExCell-400 medium) supplemented with antibiotics.
Construction of recombinant transfer vectors
A cDNA fragment containing the complete open-reading frame of human RAR-yl (nucleotides 43-1800) was excised by restriction enzyme digestion from the parent plasmid pGEM3Z-RAR-y. The 1767 bp cDNA fragment obtained was purified, and excess 5' non-coding sequences were deleted by Bal3 1 cleavage. The 5' ends were repaired with the Klenow fragment of Escherichia coli DNA polymerase I, and EcoRI restriction sites were created with EcoRi linkers using standard procedures'. The cDNA was then subcloned into the multiple cloning sites in plasmid pVL1392 to form the transfer vector pVL1392/RAR-y. The orientation of the construct was determined by restriction enzyme analysis and DNA sequencing.
Transfection and screening of recombinant virus
Sf9 cells (2 x 106 cells in a 25 ml T-flask) were co-transfected with 1,ug of AcNPV genomic DNA and 5 ,tg of the recombinant transfer vector pVL1392/RAR-y using the modified calcium phosphate co-precipitation method for insect cells [35, 36] . Following 6 days of incubation at 27°C, the cell culture medium was harvested and screened for recombinant virus. Sf9 cells were treated with limiting dilutions of recombinant virus-containing media in microtitre plates. Wells were assayed for recombinant virus by DNA dot-blot hybridization using 32P-labelled RAR-yl cDNA as probe, as described by Summers and co-workers [35, 36] . Media from positive wells were titrated by plaque assay. Plaques without polyhedra were chosen and recombinant extracellular virus was obtained by four rounds of plaque purification. Three recombinant viral clones, which contained RAR-yl cDNA, were identified. Recombinant RAR-y1 was partially purified by fp.l.c. The supernatant from recombinant-virus-infected Sf9 cells, containing approx. 60 mg of protein, was applied to a Mono Q column (8 ml) equilibrated with 20 mM-Tris/HCl (pH 7.5), 10 % glycerol and 10 mM-thioglycerol. After eluting unbound protein with equilibration buffer, RAR-yl was eluted with a 200 ml nonlinear gradient of NaCl (0-1 M). Fractions of 2 ml were collected and 0.2 ml of each fraction was analysed for RAR-yl by protein immunoblotting using a RAR-yl-specific antibody, obtained by immunization of chickens with synthetic peptides having the Cand N-terminal amino acid sequences of human RAR-yl (see below). Immunoblots were visualized with alkaline-phosphatasesecondary-antibody conjugates, and the amount of RAR-yl was estimated from the intensity of colour on a 1-10 scale, with 10 being most intense. Fractions containing RAR-y1 were pooled and concentrated by centrifugation in an Amicon Centricon 30, and then applied to a Superdex gel-filtration column (25 ml) equilibrated with 0.3 M-KPO4, 10 % glycerol and 10 mM-thioglycerol (pH 7.5). Fractions (0.5 ml) were collected and assayed as described above. Fractions containing receptors were pooled, diluted 3-fold in 75 mM-Hepes, 0.3 M-KCI, 37.5 mM-MgCl2, 3 mM-dithiothreitol, 50% glycerol and 60 ,tg of calf thymus DNA/ml, and applied to a RARE affinity column (1 ml). The column was washed with equilibration buffer to remove unbound protein, and bound RAR-yl was eluted with equilibration buffer containing 1 M-KCI. The purified receptor was stored at -20°C, and retained ligand-binding activity for at least 1 month.
Recombinant RAR-yl vaccinia virus
Construction ofrecombinant vaccinia virus expression vectors, infection of HeLa cells with these vectors and preparation of nuclear extracts from these cells has been previously described [37] .
Preparation of RARE affinity column
A DNA affinity column was prepared by covalently coupling synthetic concatamers (average size 87 bp) of the 27 bp RARE consensus sequence, found in the promoter of the RAR-,f gene, to cyanogen bromide-activated Sepharose CL-2B. The procedure has been described previously [38] . [41] . Binding data were analysed by the method of Scatchard [42] .
Gel-retardation assay
The DNA-binding properties of recombinant RAR-yl were studied by a gel-retardation assay as described by Nicholson et al. [37] . Antibodies utilized in these studies (see Fig. 7 ) have been described previously [43] .
Preparation of chicken anti-RAR-yl antibodies
Chicken egg antibodies to RAR-yl were prepared by immunization of single-comb White Leghorn laying hens (shaver stockcross 288) (16-17 months old) with 100,ug of synthetic peptide containing the N-terminal (RGLGQPDLPKEMASC) or C-terminal (CSSEDEVPGGQGKGGLKSPA) sequence of human RAR-yl, conjugated to keyhole limpet haemocyanin. The antigen was dissolved in 0.75 ml of PBS, mixed with an equal volume of complete Freund's adjuvant, and injected intramuscularly into two sites in the breast. Two groups of three chickens each were injected with the two different peptide antigens. Booster immunizations were given on days 12 and 20. Eggs were collected each day and antibodies were prepared from the yolks by precipitation with poly(ethylene glycol) 8000, as described in [44] . The antibodies were titred by e.l.i.s.a. using the appropriate unconjugated peptide as antigen and a horseradish peroxidase-conjugated goat anti-chicken second antibody. All six-chickens produced antibodies of similar titres, with maximal production between days 30 and 35. None of the three antibodies raised to the N-terminal peptide recognized the C-terminal peptide, and none of the three anti-C-terminal antibodies recognized the N-terminal peptide. For Western blot and immunodot blot analysis the antibodies were used at a dilution of 1:100, and C-and N-terminal antibodies yielded similar results.
RESULTS
Expression of RAR-yl 60 and 90 h after infection.
At times greater than 90 h post-infection, numerous bands of lower molecular mass were observed, presumably reflecting proteolysis of RAR-yl (results not shown). This degradation of RAR-yI coincided with significant viral lysis of the cells. In order to minimize protein degradation associated with cell lysis, infected cells were routinely harvested between 60 and 90 h postinfection.
To estimate the level of RAR-yl expression, the protein patterns of supernatants from uninfected and RAR-yl-infected Sf9 cells were analysed by SDS/PAGE and Western blot. A prominent protein band with apparent molecular mass of 50 kDa, which was absent from uninfected cells, was present in the supernatant from RAR-yl-infected cells (Fig. lb, lanes 1 and 2) .
Western blot analysis indicated that this band was RAR-yI (Fig.  lb, lanes 3 and 4) .
The intracellular localization of recombinant RAR-yl protein in the insect cells was analysed by Western blot analysis of nuclear and cytoplasmic fractions from infected Sf9 cells. The results indicated that RAR-yl was predominantly present in the nuclear fraction (results not shown).
Purification of recombinant RAR-yl
Recombinant RAR-yl was partially purified from Sf9 cell lysates by sequential ion-exchange, gel-filtration and affinity chromatographies. The cell lysate was centrifuged and the supernatant was applied to a Mono Q anion-exchange column connected to an f.p.l.c. system. After washing the column to remove unbound protein, RAR-yl was eluted by a gradient of NaCl (Fig. 2) . RAR-yl in the column fractions was measured by Western dot-blot. RAR-yl eluted as a single symmetrical peak between 0.25 and 0.35 M-NaCl. Fractions containing RARyl were combined, concentrated and applied to a Superdex gel- (Fig. 4) . This difference may have been due to instability of RAR-yl ligand binding during purification, and/or preferential staining of RAR-yl by Coomassie Blue, thus making it appear more prominent than it actually was.
Ligand binding of recombinant RAR-yl
Recombinant RAR-yl was incubated with [3H]RA or [3H]-CD367, a stable RA analogue known to have RAR binding characteristics similar to those of RA [28] . The mixture was applied to a size-exclusion column to separate bound from free ligand. Fig. 5(a) [41] the equilibrium dissociation constants for crude and partially purified receptors were found to be identical and varied between 0.05 and 0.3 nm for RA (Fig. Sc) and between 0.2 and 1.0 nm for the synthetic analogue CD367 (Fig. Sd) . We also compared the above results with those obtained for vaccinia-virus-expressed RAR-yl without detecting any significant differences (results not shown). 
DNA binding of recombinant RAR-yl
In gel-retardation experiments baculovirus-expressed RARyl bound specifically to synthetic DNA encompassing the RARE of the RAR-,8 gene (Fig. 7b, lane 14, complex a) . In the presence of the anti-RAR-yl specific antibody mAb4g this complex was supershifted (lane 15, complex b). No specifically retarded band was observed with mock-infected Sf9 cells (lane 9; note that a very weak band close to the position of band "aa" was not supershifted by the monoclonal antibody, as shown in lane 10). An excess of non-radioactive RARE abrogated the signal and no retarded band was seen with a mutant RARE (results not shown). Addition of CD367 to the incubation mixture containing either unpurified or purified RAR-yl and labelled RARE, prior to electrophoretic separation of the mixture, increased the mobility ofthe RAR-yl /RARE complex on long-run retardation gels, while RA had a very small, if any, effect (results not shown).
RAR-yl expressed in mammalian and insect cells binds similarly to a RARE
To investigate whether RAR-yl expressed in Sf9 cells binds to its cognate enhancer with similar potency as the receptor made in mammalian cell, we calibrated by Western blot extracts of baculovirus-and vaccinia virus-produced RAR-yI (Fig. 7a) , and compared extracts containing equal amounts of receptor in gelshift assays. As shown in Fig. 7(b), lanes 5, 6, 13 and 14, both Vol. 287 receptor preparations bound with similar efficiencies to the RARE (note that the 2-fold difference seen in this particular experiment was not seen in three other independent experiments).
DNA-binding stimulatory factors increase the efficiency of interaction of RAR-yl with the RAR-,8/RARE
Several nuclear receptors, including the RAR-al, have been reported to bind with increased efficiency to their cognate response elements in the presence of so-called DNA-binding stimulatory factors (DBSFs) [45] [46] [47] [48] [49] [50] . We tested whether DBSFs, commonly added as crude HeLa cell extracts, had an effect on the DNA binding of vaccinia virus-and baculovirus-expressed RAR-yl (Fig. 7c) . In fact, when the DNA binding of similar Western blot-calibrated amounts of the receptor (Fig. 7a) expressed in both systems was compared in the presence (Fig. 7c) and absence (Fig. 7b) of HeLa cell extract, approx. 20-50 times more RAR/RARE complexes were seen (compare Figs. 7b and  7c, lanes 4, 5, 12 and 13) . We conclude that RAR-yl expressed using either system binds equally to the RAR-,/ gene RARE, and that DBSFs present in HeLa cells strongly increase DNA complex formation and/or stability.
DISCUSSION
Emerging evidence is revealing the importance of RA in the regulation of morphogenesis during mammalian development, and in postnatal regulation of cellular growth and differentiation. This has led to a keen interest in understanding the molecular basis of the mechanism of action of RA. The molecular cloning of RARs and the demonstration of their ability to function in vitro as RA-inducible transcription enhancers has focused attention on the RARs as potential primary mediators of the biological effects of RA. However, the low level of expression of RARs in mammalian tissues has hindered detailed characterization of their functional and structural properties. Successful expression of the human RAR-yl cDNA, using the baculovirus expression system, has overcome this difficulty and provided sufficient amounts of the protein for initial characterization.
Full-length recombinant RAR-y1 displayed a molecular mass of 50 kDa by SDS/PAGE and gel-filtration chromatography, consistent with its expected size based on the deduced amino acid sequence [11] . RAR-y1 was a prominent protein, as detected by SDS/PAGE, in the soluble fraction of RAR-yl-infected Sf9 cells, indicating a high degree of overexpression. Based on ligand binding, approx. 2 x 106 receptors were expressed per Sf9 cell, a level similar to that reported for other members of the nuclear receptor family expressed in Sf9 cells, including rat [51] and human [52] glucocorticoid receptors, human oestrogen receptor [53] and mineralocorticoid receptor [54] . This level is, however, approx. 5-fold lower than the level of expression of human 1,25-dihydroxyvitamin D3 [55] and thyroid hormone bl receptors [56] .
Recombinant RAR-yl specifically bound RA and the RA analogue CD367 with similar high affinity. The Kd values for these ligands are consistent with those reported for binding by recombinant RAR-a expressed in COS cells [40] and in bacteria [57] . We observed that use of high-performance size-exclusion chromatography to separate bound from free ligand yielded apparent Kd values 5-10-fold higher than those obtained using the charcoal adsorption method. This difference may be due to loss of RAR-yl binding activity during chromatography and/or competition for ligand binding to RAR-yl by the column matrix, since free ligand is retained by the column.
Although the metabolites 4-hydroxy-RA and 4-oxo-RA have been reported to be essentially inactive [33, 34] , high concentrations (100-fold excess) of these compounds decreased binding of [3H]CD367 by recombinant RAR-yl. These data suggest that these compounds retain some residual binding capacity, and therefore may be able to activate RARs. In support of this notion, Duell et al. [58] recently found that at relatively high concentrations (ED50 values 10-fold higher than for RA), 4- hydroxy-RA and 4-oxo-RA were able to stimulate RAR-dependent reporter gene transcription. A previous study, however, failed to detect binding of4-hydroxy-and 4-oxo-RA to truncated forms of RAR-a and -fi, containing the ligand-binding domain, expressed in bacteria [59] . This may have been due to the low concentration of 4-oxidized metabolites employed, as well as a decreased affinity of the truncated receptors for ligand. Alternatively, the data may reflect differences in ligand-binding properties among RAR-a, -, and -y. Differences in the ability of the three RARs to stimulate reporter gene transcription in response to a variety of retinoids have been previously observed [60] .
Although there is little information on the physiological concentrations of4-oxidized RA metabolites in tissues, it appears that they are present in small amounts relative to RA. In human skin, which expresses high levels of RAR-yl mRNA [61] , the level of 4-hydroxy-RA was 100 times lower than that of RA, and 4-oxo-RA was undetectable, following 4 days of treatment with 0.1 % RA cream [58] . These data, taken together with the results of the binding studies, suggest that in human skin in vivo, 4 [62] . Binding of the RARE by recombinant RAR-yl was, however, independent of RA. Binding of recombinant RAR-a, expressed in bacteria, to a synthetic RARE was also found to be independent of RA [57] . Note, however, that we observed an increased mobility of RAR/RARE complexes when the receptor was exposed to CD367, suggesting a change in 1992 838
Properties of human retinoic acid receptor-yl 5) of HeLa cell extract alone. HeLa cell extracts were prepared as described [13] .
Vol. 287 receptor structure upon ligand binding. It is not known whether RARs are bound constitutively to DNA in vivo, as could be deduced from in vitro gel-retardation experiments. A modulatory role of heat shock protein 90 (hsp90), hypothesized in the case of steroid receptors [63, 64] , can apparently be excluded, since RAR/hsp90 complexes have not been observed in vitro [62] . It is thus possible that the RAR is associated with its response elements even in vivo, perhaps acting as a repressor in the absence of ligand, and that exposure to RA results in the formation (or, alternatively, unmasking) of its transcription activation function.
Recently it has been demonstrated that the DBSF present in HeLa cells, which stimulates the DNA binding of RARs, is RXRfi, and that RAR/RXR heterodimers bind more efficiently to certain RAREs than the corresponding homodimers [13, 15] . Here we observe, in accordance with that study, that both baculovirus-and vaccinia virus-produced RAR-yl require an additional factor, present in the HeLa cells extract, for optimal binding to DNA, which in view of the study by Leid et al. [13] is most likely a member of the RXR family.
In summary, we have demonstrated the feasibility ofemploying the baculovirus expression system for producing RAR-yl protein. Moreover, by comparing vaccinia virus-and baculovirusproduced RAR-yl, we have shown that RARs expressed in insect and mammalian cells are functionally (DNA and ligand binding properties) equivalent. The availability of recombinant RAR-yl will allow further detailed characterization of its role in the regulation of gene transcription. It is likely that the baculovirus expression system will be useful for expression of fulllength and mutated forms of the other RARs 
